MRK
WAITMerck & Company, Inc.
$130.20
+0.32%delayed
News – · Trend – · inside triggers –
Expected move (1d)
▼ $126.92to$133.48 ▲
ATR ±$3.28 (+2.52%)Implied ±$6.41 (+4.92%)
Entry Reference
Price / prev close$130.20 / $129.79
Day range$128.14 – $131.04
52-wk range$77.58 – $135.05(92%)
Volume vs avg0.46×
ATR (14d)$3.28
MA 8 / 21$130.24 / $127.43
MA 50 / 200$122.86 / $111.59
Call ▲ / Put ▼ trigger$130.56 / $129.02
+1 / +2 ATR$133.48 / $136.76
-1 / -2 ATR$126.92 / $123.64
Support: 125.14 124.00 123.13
Resistance: 130.29 131.74
Near-the-money contracts
exp 2026-08-07Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 128 | $4.55 | 54% | 0.62 | -0.30 | 124 |
| 129 | $4.00 | 52% | 0.57 | -0.30 | 81 |
| 130 | $3.45 | 51% | 0.53 | -0.30 | 200 |
| 131 | $2.86 | 50% | 0.48 | -0.29 | 186 |
| 132 | $2.50 | 49% | 0.43 | -0.28 | 167 |
| 133 | $2.06 | 49% | 0.38 | -0.27 | 189 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 127 | $1.82 | 48% | -0.32 | -0.24 | 77 |
| 128 | $2.19 | 49% | -0.37 | -0.26 | 198 |
| 129 | $2.43 | 46% | -0.42 | -0.25 | 69 |
| 130 | $2.96 | 46% | -0.47 | -0.25 | 178 |
| 131 | $3.33 | 46% | -0.53 | -0.25 | 50 |
| 132 | $4.08 | 46% | -0.58 | -0.25 | 79 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- SpaceX's First Earnings Post IPO12h ago
- Merck (MRK) Plans Early HIV Pill Licensing Across 129 Countries17h ago
- MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback1d ago
- Top dow jones movers in Friday's session1d ago
- The Signs Before Eli Lilly Stock Surged Were All On The Record1d ago
- Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep1d ago
- LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15%1d ago
- Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?1d ago
- No Options, No Leverage, No Gimmicks: 3 Dividend ETFs Paying Over 4 Percent the Old-Fashioned Way1d ago
- 1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm1d ago
- Here Comes the Next Wave of GLP-1s. They’ll Treat a Lot More Than Obesity.2d ago
- Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?2d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.